Trials / Completed
CompletedNCT05236673
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Jardiance® (Empagliflozin, 10mg) in Korean Patients With Chronic Heart Failure (NYHA Class II-IV)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 610 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JARDIANCE® | JARDIANCE® film-coated tablets 10mg |
Timeline
- Start date
- 2022-07-28
- Primary completion
- 2025-04-30
- Completion
- 2025-04-30
- First posted
- 2022-02-11
- Last updated
- 2025-05-16
Locations
21 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05236673. Inclusion in this directory is not an endorsement.